BALTIMORE, Sept. 20 /PRNewswire/ -- CSA Medical, Inc. announced today that New York University Langone Medical Center (NYU) has begun providing Spray Cryotherapy treatment for patients. Dr. Costas (Gus) Bizekis, Assistant Professor of Medicine, in the department of Cardiothoracic Surgery is performing this procedure. Dr. Bizekis is the Director of Esophageal Surgery in the Department of Cardiothoracic Surgery at NYU Langone Medical Center. Dr. Bizekis has extensive experience in all aspects of esophageal disease management.
"Spray Cryotherapy is an exciting addition to the tools offered at NYU as it is a minimally invasive (endoscopic) approach that is very patient friendly," says Dr. Bizekis. "We freeze and kill the unwanted tissue with very little pain and patients can generally return to work the next day. Some patients are not candidates for surgery or they have failed to respond to other treatments like chemotherapy and radiation and spray cryotherapy gives us another option. Recently published data also demonstrates it to be safe and effective as a first-line or primary therapy."
Spray cryotherapy utilizes ultra-cold (-196 degrees C) liquid nitrogen delivered in a low pressure spray to freeze and destroy unwanted tissue in the body.
"We are thrilled to have NYU as our 75th customer. It is fitting that such a world-class, patient centered, integrated academic medical center would mark a landmark event for the company" said Ric Hughen, Vice President-Sales & Marketing. "NYU joins a group of preeminent medical centers on the leading edge of new technology adoption for the benefit of their patients".
CSA Medical, Inc. develops and manufactures a proprietary therapeutic interventional platform, the CryoSpray Ablation™ System. The CSA System utilizes a patented spray cryogenic technology that allows a physician to freeze and destroy a wide range of unwanted tissues via an endoscope.
|SOURCE CSA Medical, Inc.|
Copyright©2010 PR Newswire.
All rights reserved